Phaseline

Companies › Lumos Pharma

Lumos Pharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LUM-201
Growth hormone secretagogue
–Phase 3Growth Hormone Deficiency (GHD); Growth Hormone DeficiencyDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06948214LUM-201Phase 3Growth Hormone Deficiency (GHD)Metabolic and endocrineDec 2027
NCT04806854LUM-201Phase 2Growth Hormone DeficiencyMetabolic and endocrineApr 2030

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Neuvosyn Laboratories

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.